Development of pegylated interferons for the treatment of chronic hepatitis C.
about
Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in MiceImpact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricaseA multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats.Safety, Tolerability, and Immunogenicity of InterferonsPeginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B.Enhanced aqueous solubility of long wavelength voltage-sensitive dyes by covalent attachment of polyethylene glycol.Biodegradable nanogels for oral delivery of interferon for norovirus infectionPeginterferon-alpha2a (40 kDa) for chronic hepatitis C.Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway.Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B.PEGylated bioactive molecules in biodegradable polymer microparticles.A radiopaque polymer hydrogel used as a fiducial marker in gynecologic-cancer patients receiving brachytherapy.Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery.Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages.Optimizing the treatment of chronic viral hepatitis C.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.Genetic basis of MPN: Beyond JAK2-V617F.Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation.Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy.Synthesis and antimalarial activity of ethylene glycol oligomeric ethers of artemisinin.Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report.New biological therapies from the human genome.
P2860
Q27473398-201D8269-649D-4746-A6DD-FF4F01AB8DFAQ28727969-40A8C76D-AF1A-47FE-B531-787E7E95B791Q33393458-99DB4102-53C2-43AD-947D-61A434454188Q33435810-25DD1793-6C81-4A4D-85EF-6AED0DB254F6Q33989405-A27EC3F1-3FEB-4EAF-A9D1-0501D611A5F5Q34493233-C163006A-0C6A-4E0C-8FFB-FCCEB48AD9A7Q34525191-41896A4C-426C-4FE4-9E73-E8F867170918Q35095217-D3B65E5B-CFF9-436B-9065-9DBDB8C96A67Q36007339-5A0CE6D8-52B8-49EF-B8FF-FFCC94D9A994Q36311347-97156387-DC2E-4960-9D2D-62008C2BAC13Q36918763-E6C1E798-CAD3-4274-9D9B-29A05DF18A74Q36922266-1A427DCE-E75A-49EB-A439-A440BDDBDBFFQ37023070-49AF399A-19DA-4467-84F7-21B53F274D5AQ37037077-BAF3157B-AFAE-44F2-B5EC-F0EC1AB147EFQ37192494-5E4AD10F-E27E-479E-88C2-683F2DC106FDQ37254462-9BFFD805-6A2F-4A0B-AB8C-3F9AF03431FBQ37310990-31737212-AAED-42A0-93F8-38DBE4FF6722Q37636095-7F09D7C8-02EC-4F12-8919-D378A2D8D3CAQ37955231-55449676-5666-4C10-8917-FD943734CE76Q38159973-CD401A9B-0223-4BC1-BE08-2BF2320CAE2BQ38187684-DD8EB44E-E2F6-43BB-8F6B-B88505191D61Q38255726-7ADD731A-D1C7-4008-B772-A617713B11B8Q38584280-97F53158-D419-42FA-ACF0-1951862D3AE9Q38774457-63AAE9E6-1E90-4D30-B6E9-1965F64408AFQ39279201-B792D6D4-1716-4D27-A0BB-1BA6A7CF4000Q40481236-0654E627-D9B8-44ED-9C24-6EE4178C80EAQ40707634-036B406F-5BC6-4734-97D2-1C24810E3721Q41933892-78C33CD0-C428-430F-A120-2C485317D608Q47245228-C2AE26BA-8777-4FD9-822B-0A888BE3F7F5Q51016737-DF59047A-A2BB-41E1-B59A-EB28A2D0C8CF
P2860
Development of pegylated interferons for the treatment of chronic hepatitis C.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Development of pegylated interferons for the treatment of chronic hepatitis C.
@ast
Development of pegylated interferons for the treatment of chronic hepatitis C.
@en
Development of pegylated interferons for the treatment of chronic hepatitis C.
@nl
type
label
Development of pegylated interferons for the treatment of chronic hepatitis C.
@ast
Development of pegylated interferons for the treatment of chronic hepatitis C.
@en
Development of pegylated interferons for the treatment of chronic hepatitis C.
@nl
prefLabel
Development of pegylated interferons for the treatment of chronic hepatitis C.
@ast
Development of pegylated interferons for the treatment of chronic hepatitis C.
@en
Development of pegylated interferons for the treatment of chronic hepatitis C.
@nl
P2093
P1433
P1476
Development of pegylated interferons for the treatment of chronic hepatitis C.
@en
P2093
A Kozlowski
J M Harris
S A Charles
P304
P356
10.2165/00063030-200115070-00001
P577
2001-01-01T00:00:00Z
P5875
P6179
1039768826